Asset profile

MK-4646

Small molecule

Phase 1Undisclosed / early pipeline
Weaksignal

Evidence outlook · lead readout

NCT07042945 · HIV Infection

The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.

NCT07042945: All participants received active drug in one of four dose panels with no placebo or comparator group and no blinding, so this trial cannot demonstrate a treatment effect on its own; results have not yet been reported.

How the evidence outlook works ↗

Upcoming events

No upcoming readouts on record for this asset.

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.